The slow adoption of CBD as a potential treatment for common mental health problems like insomnia and anxiety is gaining traction. Consumers are already buying CBD oil, foods and other products to treat anxiety and depression. For example, a 2019 Gallup survey found that 14% of Americans use CBD products for a variety of reasons.
About 20% use CBD oil to treat anxiety and 11% to treat insomnia, with 40% citing pain relief as the main reason for using CBD products. According to the survey, the largest number of CBD users is between 18 and 29 (20%), with the over 65 age group being 8%.
Among people using CBD, about 40% use it for pain relief, but more women than men use products for anxiety relief (25% and 14%, respectively). Conversely, more men than women use CBD products to treat insomnia (15% and 8%, respectively). And now a landmark US study has just been announced investigating its potential as a treatment for anxiety.
Due to the rapidly growing interest in CBD among people around the world, there is a growing need for more controlled clinical trials of the efficacy of a cannabis derivative. Real world data (RWD) at a large scale is vital to collect information from real users in real time so that product developers can deliver what they need.